-
Potential MS ‘Preventive’ Treatment, T20K, Seen To Be Safe in Phase 1 Study
A first trial found T20K, Cyxone‘s plant protein-derived MS therapy, safe and well-tolerated in healthy men, with blood levels evident at a very low dose. Read more about it here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.